Fostamatinib for severe lung failure in hospitalized adults
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a drug called fostamatinib to treat severe lung failure (ARDS) in people who are on a breathing machine. The goal is to see if it helps the lungs recover faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are in the hospital and on a breathing machine (ventilator) for severe lung failure (ARDS).
- You have had a CT scan of your chest in the last week.
- You have been on the breathing machine for less than 10 days.
- If there is any chance you could become pregnant, you agree to use effective birth control during the study and for 30 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LEAF-4L6715 to see if it helps people with severe acute respiratory distress syndrome (ARDS), a serious lung condition. If you are on a breathing machine and meet the criteria below, you may be able to join.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This study tests if adding a type of steroid (glucocorticoid) to standard treatment helps people on a breathing machine recover from severe lung failure (ARDS). It compares different doses to see which works best.
This trial tests a drug called fostamatinib to see if it is safe and tolerable for lung transplant patients who develop new antibodies against their donor lung. It aims to prevent rejection without harming the new lung.
This Phase 3 trial tests whether pirfenidone can prevent or reduce lung scarring (fibrosis) in adults with ARDS who are within about a week of their illness starting. It may help by lowering harmful inflammation and the body’s scarring response.
This Phase 1 study tests whether increasing doses of fostamatinib are safe and tolerated in adults with stable sickle cell disease. It may help researchers understand if the drug could be a future treatment option for people with stable sickle cell.
Hear when a new Acute Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.